Serum, Cerebrospinal Fluid, and Brain Concentrations of a New Zidovudine Formulation following Chronic Administration via an Implantable Pump in Dogs
- 1 January 1992
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 81 (1) , 11-15
- https://doi.org/10.1002/jps.2600810103
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Safety and tolerance of intermittent intravenous and oral zidovudine therapy in human immunodeficiency virus-infected pediatric patientsThe Journal of Pediatrics, 1990
- Comparative pharmacokinetics and interspecies scaling of 3'-azido-3'-deoxythymidine(AZT) in several mammalian species.Journal of Pharmacobio-Dynamics, 1990
- Pump delivery of azidothymidine: Potential for constant concentrations and improved brain deliveryJournal of Controlled Release, 1989
- Pharmacokinetics of subcutaneous azidothymidine in rhesus monkeysAntimicrobial Agents and Chemotherapy, 1989
- Effect of Continuous Intravenous Infusion of Zidovudine (AZT) in Children with Symptomatic HIV InfectionNew England Journal of Medicine, 1988
- The Brain in AIDS: Central Nervous System HIV-1 Infection and AIDS Dementia ComplexScience, 1988
- 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.Proceedings of the National Academy of Sciences, 1985
- Regional chemotherapy of neoplastic diseasesPharmacology & Therapeutics, 1983
- Pharmacokinetic Model for Simultaneous Determination of Drug Levels in Organs and TissuesJournal of Pharmaceutical Sciences, 1976
- Hydrocephalus: Changes in Formation and Absorption of Cerebrospinal Fluid Within the Cerebral VentriclesJournal of Neurosurgery, 1963